{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-24-022271","form_type":"8-K","ticker":"RFL","cik":"0001713863","company_name":"Rafael Holdings, Inc.","filed_at":"2024-03-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.220679+00:00","generated_at":"2026-06-04T19:52:10.345601+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Rafael Holdings Q2 fiscal 2024 net income $5.9M; Day Three Labs stake raised to 79%","bullets":["Net income from continuing ops $5.9M ($0.25 diluted EPS) vs loss of $3.3M (-$0.13) YoY.","Cash and marketable securities $71.7M at Jan 31, 2024.","Investment in Cyclo Therapeutics contributed $9.7M unrealized gain; Day Three Labs loss $1.6M.","Increased ownership in Day Three Labs to 79% majority interest; consolidating results.","Appointed Dr. John Goldberg as Chief Medical Officer."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-24-022271","json":"https://secwatch.observer/filing/0001213900-24-022271.json","markdown":"https://secwatch.observer/filing/0001213900-24-022271.md","text":"https://secwatch.observer/filing/0001213900-24-022271.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024022271/0001213900-24-022271-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024022271/ea0201707-8k_rafael.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-04T19:52:10.345601+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"d7746d0277d18e215132cec7c42d4953737ebdac","claim":"Rafael Holdings, Inc. reported second quarter of fiscal 2024 results: net income net income from continuing operations of $5.9 million, EPS $0.25 per fully diluted share.","evidence_excerpt":"For the three months ended January 31, 2024, we recorded net income from continuing operations of $5.9 million, or $0.25 per fully diluted share","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1713863/000121390024022271/0001213900-24-022271-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter of fiscal 2024"},{"label":"Net income","value":"net income from continuing operations of $5.9 million"},{"label":"EPS","value":"$0.25 per fully diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}